Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak

Abstract

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge

“…At the beginning of the pandemic, the case fatality rate of CLL patients with COVID‐19 was reported to be as high as 33% 5 and declined to 11% in the second wave 8 . In our study, the mortality rate during the Omicron surge is similar to that previously reported during the same period in patients with CLL 2,3 . Our findings are further consistent with the continuously decreased mortality in patients with CLL throughout the later pandemic waves, as noted above.…”

“…8 In our study, the mortality rate during the Omicron surge is similar to that previously reported during the same period in patients with CLL. 2,3 Our findings are further consistent with the continuously decreased mortality in patients with CLL throughout the later pandemic waves, as noted above. The declined mortality may be best explained by better clinical management with the use of pre-exposure prophylaxis of COVID-19 (tixagevimab/cilgavimab) and anti-viral drugs (ritonavirboosted nirmatrelvir and molnupiravir), which were more commonly administrated during the dominance of the BA.2 and BA.5 subvariants.…”

“…

Recent studies performed during the early period (December 2021-April 2022) of the omicron (B.1.1.529) variant of concern and its subvariants, suggested favourable clinical outcomes compared with earlier SARS-CoV-2 variants in patients with chronic lymphocytic leukaemia (CLL). [1][2][3] However, the outcomes of CLL patients infected in the later period of the omicron subvariants are not fully elucidated.In this single-center, retrospective study, we analysed the all-cause hospitalization and 30-day mortality of CLL patients infected with SARS-CoV-2 from December 2021 through November 2022. The diagnosis of SARS-CoV-2 infection was confirmed by a positive reverse transcriptionpolymerase chain reaction assay or an antigen test at authorized testing sites on nasopharyngeal swabs.

…”

“…Recent studies performed during the early period (December 2021-April 2022) of the omicron (B.1.1.529) variant of concern and its subvariants, suggested favourable clinical outcomes compared with earlier SARS-CoV-2 variants in patients with chronic lymphocytic leukaemia (CLL). [1][2][3] However, the outcomes of CLL patients infected in the later period of the omicron subvariants are not fully elucidated.…”

Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study

“…2,17,18 Similar results were shown in additional studies conducted during the Omicron outbreak, which reported hospitalization rates of 26%-43% and mortality rates of 4%-12% in cohorts that included hemato-oncology patients. [19][20][21][22][23] We evaluated factors that were associated with COVID-19 disease severity, using the National Institute of Health criteria. This classification incorporates respiratory parameters to categorize the COVID-19 status.…”